Media stories about Galectin Therapeutics (NASDAQ:GALT) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Galectin Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.5845291007937 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
A number of equities analysts recently issued reports on the stock. ValuEngine cut shares of Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 21st. Roth Capital dropped their price target on shares of Galectin Therapeutics from $10.00 to $3.00 and set a “buy” rating on the stock in a research note on Thursday, December 7th. Seaport Global Securities reiterated a “buy” rating and issued a $5.00 price target on shares of Galectin Therapeutics in a research note on Friday, October 6th. Zacks Investment Research cut shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 8th. Finally, HC Wainwright upped their price target on shares of Galectin Therapeutics from $3.50 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, November 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $5.55.
Galectin Therapeutics (GALT) opened at $5.87 on Friday. Galectin Therapeutics has a 52-week low of $0.94 and a 52-week high of $6.15. The firm has a market capitalization of $209.20, a PE ratio of -10.67 and a beta of 2.54.
Galectin Therapeutics (NASDAQ:GALT) last issued its earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. analysts anticipate that Galectin Therapeutics will post -0.52 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/14/galectin-therapeutics-galt-getting-somewhat-positive-press-coverage-analysis-finds.html.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.